本帖最后由 老马 于 2012-1-13 21:20 编辑
9 G9 J: v3 X. B' C
) N9 U8 d @/ s7 v4 G爱必妥和阿瓦斯丁的比较
( V# {3 N6 N, F. P. j
2 ~! c6 e" E& C) Z3 r5 N5 ]. Ghttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
$ g: w4 @# J2 t1 |, [
" F% [4 L& ^4 B' _8 X% h8 E# i# U
+ t: z0 ~3 X4 N+ |* z2 Chttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ p8 K3 ~+ u0 [0 T
==================================================
* v8 K' M3 V9 \( D U. _: KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)7 F! P- r) m. o+ J: j
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.( `% z, Q7 Y6 O& z6 g
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* [; P8 e6 _9 I5 d" R8 z
|